Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women

[1]  G. Schmitz,et al.  Expression of the Receptor for Advanced Glycation End Products in Epicardial Fat: Link with Tissue Thickness and Local Insulin Resistance in Coronary Artery Disease , 2015, Journal of diabetes research.

[2]  G. Schmitz,et al.  Epicardial adipose tissue inflammation is related to vitamin D deficiency in patients affected by coronary artery disease. , 2015, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[3]  M. Woodward,et al.  Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity? , 2015, The Journal of clinical endocrinology and metabolism.

[4]  Y. Higashimoto,et al.  DNA Aptamer Raised Against Advanced Glycation End Products (AGEs) Improves Glycemic Control and Decreases Adipocyte Size in Fructose-Fed Rats by Suppressing AGE-RAGE Axis , 2014, Hormone and Metabolic Research.

[5]  Standards of Medical Care in Diabetes—2015: Summary of Revisions , 2014, Diabetes Care.

[6]  Peter J. Psaltis,et al.  Epicardial adipose tissue: far more than a fat depot. , 2014, Cardiovascular diagnosis and therapy.

[7]  R. Sacco,et al.  Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study. , 2014, Metabolism: clinical and experimental.

[8]  M. V. van Zandvoort,et al.  N&egr;-(Carboxymethyl)lysine-Receptor for Advanced Glycation End Product Axis Is a Key Modulator of Obesity-Induced Dysregulation of Adipokine Expression and Insulin Resistance , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[9]  J. Pankow,et al.  Genome-wide association study identifies common loci influencing circulating glycated hemoglobin (HbA1c) levels in non-diabetic subjects: the Long Life Family Study (LLFS). , 2014, Metabolism: clinical and experimental.

[10]  R. Nagatomi,et al.  Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study , 2014, Diabetology & Metabolic Syndrome.

[11]  Y. Hung,et al.  Soluble Form of Receptor for Advanced Glycation End Products Is Associated with Obesity and Metabolic Syndrome in Adolescents , 2014, International journal of endocrinology.

[12]  A. Gastaldelli,et al.  Imaging cardiac fat. , 2013, European heart journal cardiovascular Imaging.

[13]  Bruce Bartholow Duncan,et al.  Epicardial Fat: Definition, Measurements and Systematic Review of Main Outcomes , 2013, Arquivos brasileiros de cardiologia.

[14]  B. Astor,et al.  sRAGE and Risk of Diabetes, Cardiovascular Disease, and Death , 2013, Diabetes.

[15]  C. Stehouwer,et al.  Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity , 2013, Current opinion in lipidology.

[16]  Nalaka Gooneratne,et al.  Single Slice vs. Volumetric MR Assessment of Visceral Adipose Tissue: Reliability and Validity Among the Overweight and Obese , 2012, Obesity.

[17]  G. Schmitz,et al.  Il-18 Level in Patients Undergoing Coronary Artery Bypass Grafting Surgery or Valve Replacement: Which Link with Epicardial Fat Depot? , 2012, International journal of immunopathology and pharmacology.

[18]  J. Després,et al.  Body Fat Distribution and Risk of Cardiovascular Disease: An Update , 2012, Circulation.

[19]  F. Chiarelli,et al.  Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children? , 2012, Antioxidants & redox signaling.

[20]  S. Fukumoto,et al.  Receptor for Advanced Glycation End Products Regulates Adipocyte Hypertrophy and Insulin Sensitivity in Mice Involvement of Toll-Like Receptor 2 , 2012 .

[21]  G. Hitman,et al.  Total Soluble and Endogenous Secretory Receptor for Advanced Glycation End Products as Predictive Biomarkers of Coronary Heart Disease Risk in Patients With Type 2 Diabetes , 2011, Diabetes.

[22]  F. Saremi,et al.  Quantification of epicardial adipose tissue: correlation of surface area and volume measurements. , 2011, Academic radiology.

[23]  Andre Lamy,et al.  Epicardial fat thickness and coronary artery disease correlate independently of obesity. , 2011, International journal of cardiology.

[24]  J. Baillargeon,et al.  Gestational Diabetes Mellitus: Simplifying the International Association of Diabetes and Pregnancy Diagnostic Algorithm Using Fasting Plasma Glucose , 2010, Diabetes Care.

[25]  R. Seibel,et al.  Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. , 2010, Atherosclerosis.

[26]  F. Sardanelli,et al.  Relation of echocardiographic epicardial fat thickness and myocardial fat. , 2010, The American journal of cardiology.

[27]  S. Shah,et al.  Gestational diabetes: simplifying the IADPSG diagnostic algorithm using fasting plasma glucose , 2010 .

[28]  F. Santilli,et al.  Soluble forms of RAGE in internal medicine , 2009, Internal and emergency medicine.

[29]  A. Heidland,et al.  Plasma advanced glycation end products are decreased in obese children compared with lean controls. , 2009, International journal of pediatric obesity : IJPO : an official journal of the International Association for the Study of Obesity.

[30]  H. J. Yoo,et al.  Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. , 2009, International journal of cardiology.

[31]  G. Norata,et al.  Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. , 2009, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[32]  S. Colagiuri,et al.  International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[33]  Udo Hoffmann,et al.  Pericardial Fat, Visceral Abdominal Fat, Cardiovascular Disease Risk Factors, and Vascular Calcification in a Community-Based Sample: The Framingham Heart Study , 2008, Circulation.

[34]  G. Basta.  Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. , 2008, Atherosclerosis.

[35]  A. Ohnishi,et al.  Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[36]  T. Imaizumi,et al.  Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. , 2007, Diabetes research and clinical practice.

[37]  A. Rossi,et al.  Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[38]  M. Borggrefe,et al.  Volumetric Assessment of Epicardial Adipose Tissue With Cardiovascular Magnetic Resonance Imaging , 2007, Obesity.

[39]  T. Imaizumi,et al.  Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. , 2006, Metabolism: clinical and experimental.

[40]  HidenoriKoyama,et al.  Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis , 2005 .

[41]  S. Fukumoto,et al.  Plasma Level of Endogenous Secretory RAGE Is Associated With Components of the Metabolic Syndrome and Atherosclerosis , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[42]  H. Kahn,et al.  The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison , 2005, BMC cardiovascular disorders.

[43]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[44]  K. Preissner,et al.  The Pattern Recognition Receptor (RAGE) Is a Counterreceptor for Leukocyte Integrins , 2003, The Journal of experimental medicine.

[45]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[46]  J. Loscalzo.  Endothelium, Nitric Oxide, and Atherosclerosis: From Basic Mechanisms to Clinical Implications , 2000 .

[47]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[48]  P. Malherbe,et al.  cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. , 1999, Brain research. Molecular brain research.

[49]  M. Neurath,et al.  RAGE Mediates a Novel Proinflammatory Axis A Central Cell Surface Receptor for S100/Calgranulin Polypeptides , 1999, Cell.

[50]  J. Seidell,et al.  Techniques for the measurement of visceral fat: a practical guide. , 1993, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity.